Bonanni P, Ceddia F, Dawson R. A call to action: current challenges and considerations for COVID-19 vaccination in immunocompromised populations. J Infect Dis. 2023;228(Supplement_1):S70–S6.

Article  PubMed  PubMed Central  Google Scholar 

Hussein T, Hammad MH, Fung PL, Al-Kloub M, Odeh I, Zaidan MA, Wraith D. COVID-19 pandemic development in Jordan—short-term and long-term forecasting. Vaccines. 2021;9(7):728.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Qerem W, Jarab A, Shawabkeh Y, Ling J, Hammad A, Ba A, Alasmari F. COVID-19 vaccination booster dose: knowledge, practices, and intention among pregnant/planning to get pregnant and lactating women. Vaccines. 2023;11(7):1249.

Article  PubMed  PubMed Central  Google Scholar 

Kokogho A, Crowell TA, Aleissa M, Lupan AM, Davey S, Park Chang JB, et al. SARS-CoV-2 vaccine-induced immune responses among hematopoietic stem cell transplant recipients. Open forum Infect Dis. 2023;10(7):ofad349.

Article  PubMed  PubMed Central  Google Scholar 

Huang A, Cicin-Sain C, Pasin C, Epp S, Audigé A, Müller NJ, et al. Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation. Transplant cellular Therapy. 2022;28(4):214–e1-e11.

Article  Google Scholar 

Ram R, Hagin D, Kikozashvilli N, Freund T, Amit O, Bar-On Y, et al. Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HCT or CD19-based CART therapy—a single-center prospective cohort study. Transplant cellular therapy. 2021;27(9):788–94.

Article  CAS  Google Scholar 

Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. EClinicalMedicine. 2023;59:101983.https://doi.org/10.1016/j.eclinm.2023.101983. 

Mamez A-C, Pradier A, Giannotti F, Petitpas A, Urdiola MF, Vu D-L, et al. Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2021;56(12):3094–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhakal B, Abedin S, Fenske T, Chhabra S, Ledeboer N, Hari P, Hamadani M. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. Blood J Am Soc Hematol. 2021;138(14):1278–81.

CAS  Google Scholar 

Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abid MA, Abid MB. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: a systematic review and preliminary observations. Hematol Oncol. 2022;40(2):287–91.

Article  CAS  PubMed  Google Scholar 

O-k C, Gomez-Arteaga A, Chen Z, Soave R, Shore T, Mayer S, et al. Predictors of Covid-19 Vaccination Response After In-Vivo T-Cell–Depleted Stem Cell Transplantation. Transplant Cellular Therapy. 2022;28(9):618–e1-e10.

Google Scholar 

Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AA, Garonzik-Wang JM, Segev DL. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330–2.

Article  PubMed  Google Scholar 

Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244–6.

Article  PubMed  Google Scholar 

Peled Y, Ram E, Lavee J, Segev A, Matezki S, Wieder-Finesod A, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2022;41(2):148–57.

Article  PubMed  Google Scholar 

Redjoul R, Le Bouter A, Parinet V, Fourati S, Maury S. Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT. Lancet Haematol. 2021;8(10):e681–e3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pettini E, Ciabattini A, Pastore G, Polvere J, Lucchesi S, Fiorino F, et al. A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses. Blood Adv. 2022;6(7):2247–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85.

Article  CAS  PubMed  Google Scholar 

Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73.

Article  CAS  PubMed  Google Scholar 

Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9.

Barker TH, Habibi N, Aromataris E, Stone JC, Leonardi-Bee J, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias quasi-experimental studies. JBI Evid Synth. 2024;22(3):378-88.

Chang X, Luis F-K, Suhail ARD. DOIPLOT: Stata module for visualization of asymmetry and heterogeneity in meta-analysis. Statistical Software Components S459011 ed: Boston College Department of Economics; 2021.

Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014;72(1):39.

Article  PubMed  PubMed Central  Google Scholar 

Barkhordar M, Chahardouli B, Biglari A, Ahmadvand M, Bahri T, Alaeddini F, et al. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response—a prospective, single-arm study. Front Immunol. 2023;14:1169666.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharifi Aliabadi L, Karami M, Barkhordar M, Hashemi Nazari SS, Kavousi A, Ahmadvand M, Vaezi M. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blindedrandomized controlled trial. Front Immunol. 2023;14:1237916. https://doi.org/10.3389/fimmu.2023.1237916. 

Tsoutsoukis M, Easdale S, Anthias C, Ethell M, Arias C, Ismail S, Mir F, Shea R, Neoh C, Nicholson E. Re-vaccination against SARS-COV2 in allogeneic HSCT patients: Repeated primary vaccines doses increases seroconversion rates. Br J Haematol. 2023:59-59.

Debie Y, Vandamme T, Goossens ME, Van Dam PA, Peeters M. Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer. Eur J Cancer. 2022;163:177–9.

Article  CAS  PubMed  Google Scholar 

Canti L, Ariën KK, Desombere I, Humblet-Baron S, Pannus P, Heyndrickx L, et al. Antibody response against SARS-CoV-2 Delta and omicron variants after third-dose BNT162b2 vaccination in Allo-HCT recipients. Cancer Cell. 2022;40(4):335–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ram R, Freund T, Halperin T, Ben-Ami R, Amit O, Bar-On Y, et al. Immunogenicity of a third dose of the BNT162b2 mRNA Covid-19 vaccine in patients with impaired B cell reconstitution after cellular therapy—a single center prospective cohort study. Transplant cellular Therapy. 2022;28(5):278–e1-e4.

Article  Google Scholar 

Fatobene G, Santos CF, Otuyama LJ, Fernandes TH, Lima AHSB, Moraes BDGC, et al. Immunogenicity and safety of a heterologous COVID-19 vaccine regimen in hematopoietic stem cell transplant recipients. Transplant Cellular Therapy. 2023;29(2):S331.

Article  Google Scholar 

Henig I, Isenberg J, Yehudai-Ofir D, Leiba R, Ringelstein-Harlev S, Ram R, et al. Third BNT162b2 mRNA SARS-CoV-2 vaccine dose significantly enhances immunogenicity in recipients of allogeneic hematopoietic stem cell transplantation. Vaccines. 2023;11(4):775.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AE, Van Doesum JA, Van Binnendijk RS, et al. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA oncol. 2022;8(10):1477–83.

Article  PubMed  PubMed Central  Google Scholar 

Albiol N, Lynton-Pons E, Aso O, Moga E, Vidal S, Gómez-Pérez L, Santiago JA, Triquell M, Roch N, Lázaro E, González I, López-Contreras J, Esquirol A, Sierra J, Martino R, García-Cadenas I. mRNA-1273 SARS-CoV-2 vaccine in recently transplanted allogeneic hematopoietic cell transplant recipients: Dynamics of cellular and humoral immune responses and booster effect. Leuk Res. 2023;132:107347. https://doi.org/10.1016/j.leukres.2023.107347.

Einarsdottir S, Martner A, Nicklasson M, Wiktorin HG, Arabpour M, Törnell A, et al. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematol. 2022;107(6):1479.

Article  CAS  Google Scholar 

Kokogho A, Crowell TA, Aleissa M, Lupan A-M, Davey S, Park Chang JB, et al., editors. SARS-CoV-2 Vaccine-Induced Immune Responses Among Hematopoietic Stem Cell Transplant Recipients. Open Forum Infectious Diseases; 2023: Oxford University Press US.

Marco I, Spalliera I, Mallegni F, Mercante L, Imeneo A, Crea A, et al., editors. 1970. SARS-CoV-2 T-cell specific responses in allogeneic hematopoietic stem cell transplant recipients after second and third dose of BNT162b2 mRNA vaccine. Open Forum Infectious Diseases; 2022: Oxford University Press.

Thümmler L, Koldehoff M, Fisenkci N, Brochhagen L, Horn PA, Krawczyk A, Lindemann M. Cellular and humoral immunity after the third vaccination against SARS-CoV-2 in hematopoietic stem-cell transplant recipients. Vaccines. 2022;10(6):972.

Article  PubMed  PubMed Central  Google Scholar 

Kimura M, Ferreira VH, Kothari S, Pasic I, Mattsson JI, Kulasingam V, et al. Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients. Transplant cellular therapy. 2022;28(10):706–e1-e10.

Article  Google Scholar 

Wu X, Wang L, Shen L, He L, Tang K. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients. J Hematol Oncol. 2022;15(1):81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bailey AJM, Maganti HB, Cheng W, Shorr R, Arianne Buchan C, Allan DS. Humoral and cellular response of transplant recipients to a third dose of mRNA SARS-CoV-2 vaccine: a systematic review and Meta-analysis. Transplant. 2023;107(1):204–15.

Article  CAS  Google Scholar 

Uyemura BS, Abid MA, Suelzer E, Abid MB. Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients–targeting the target antigen. Bone Marrow Transplant. 2022;57(11):1727–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ge C, Du K, Luo M, Shen K, Zhou Y, Guo K, et al. Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Experiment hematol oncol. 2022;11(1):46.

Article  CAS